November 24, 2025 — Leads & Copy — Quince Therapeutics, Inc. (Nasdaq: QNCX) announced that senior management will participate in three investor events in December 2025.
Quince’s Chief Executive Officer and Chief Medical Officer, Dirk Thye, M.D., will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, starting at 10:30 a.m. Eastern Time. The fireside chat will be accessible on the Events page of Quince’s Investor Relations website, with an archive of the webcast available shortly after the live event.
Quince’s President, Charles Ryan, J.D., Ph.D., will participate in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025. He will be on a panel showcasing rare disease companies with key near-term catalysts as Quince moves toward pivotal Phase 3 NEAT clinical trial topline results expected in the first quarter of 2026.
Thye and Quince’s Chief Operating Officer and Chief Business Officer, Brendan Hannah, will participate in a virtual Lunch with LifeSci Featuring Quince Therapeutics fireside chat hosted by LifeSci Advisors on Tuesday, December 16, 2025, starting at 1:00 p.m. Eastern Time. Registration for the Lunch with LifeSci event is available online.
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a biotechnology company focused on rare diseases, dedicated to unlocking the power of a patient’s own biology for treatment.
Source: Quince Therapeutics, Inc.
Source: Quince Therapeutics
